FOXO4-DRI
Also known as: FOXO4-D-Retro-Inverso
FOXO4-DRI is a D-retro-inverso peptide designed to disrupt the FOXO4-p53 interaction in senescent cells. It is studied as a senolytic agent that selectively induces apoptosis in senescent cells while sparing normal cells.
Pricing for FOXO4-DRI
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
COAs for FOXO4-DRI
14 third-party tests across 7 vendors. Each card links to the full report.
For
FOXO4-DRI
by Verified Peptides· batch FOX062602108
For
FOXO4-DRI
by BioLongevity Labs· batch 261153
For
FOXO4-DRI
by Skye Peptides· batch FOX26-15-001
For
FOXO4-DRI
by Ascension Peptides· batch 55-01260229
For
FOXO4-DRI
by Ascension Peptides· batch 55-01260229
For
FOXO4-DRI
by Glacier Aminos· batch FOX10GA01
For
FOXO4-DRI
by Verified Peptides· batch 03-25-0110A
For
FOX-04
by Simple Peptide· batch cmp9xk4yj00329trx7cgpf22y
For
FOXO4-DRI
by Peptide Tech· batch F4D-5195
For
FOXO4-DRI
by BioLongevity Labs· batch cmojb7f8i01b6kirxq6ddannn
For
FOXO4-DRI
by BioLongevity Labs· batch cmojb7qk401dukirxq2vhxw8n
Purity not on file
For
FOXO4-DRI
by Skye Peptides· batch FOX26-15-001
Purity not on file
For
FOXO4-DRI
by Peptide Tech· batch F4D-5195
Purity not on file
For
FOXO4-DRI
by Verified Peptides· batch 03-25-0110A
12 citations indexed for FOXO4-DRI
review · 2026
Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline
Cellular senescence, driven by the interaction between FOXO4 and p53, is increasingly recognized as a crucial mechanism in brain aging and the development of neurodegenerative disorders.
review · 2026
The right time, the right cell: the potential for precision senotherapy in pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a fatal vasculopathy driven by proinflammatory signaling that leads to pulmonary vascular remodeling and ultimately, right ventricular failure. Existing therapies fail to eliminate dysfunctional cells or reverse pathologic remodeling.
review · 2026
Dual Roles and Therapeutic Prospects of Proximal Tubular Epithelial Cell Senescence in Acute Kidney Injury
Acute kidney injury (AKI), a life-threatening disorder marked by abrupt renal dysfunction, is increasingly recognized as a global healthcare challenge. It not only triggers immediate organ dysfunction but also heightens long-term risks of chronic kidney disease (CKD).
animal · 2025
FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway
Objectives Endothelial cell dysfunction during aging is a key driver of vascular aging and related diseases; however, effective strategies to selectively eliminate senescent endothelial cells and restore vascular function remain lacking.
review · 2025
Senotherapeutics for Brain Aging Management
Brain aging is a progressive process marked by cellular dysfunction, chronic inflammation, and increased susceptibility to neurodegenerative diseases.
Study · 2025
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI
A central process contributing to the phenotype of aging is cellular senescence. We recently identified the FOXO4 - p53 axis as pivotal in maintaining the viability of senescent cells, and that senescent cells can be targeted selectively with the senolytic peptide FOXO4-DRI.